Positive topline data from the ALBATROSS Phase II study suggest Galapagos's GLPG2222 is well tolerated and could bring additional therapeutic benefits to cystic fibrosis patients.
Galapagos NV has reported positive topline data from the Phase II ALBATROSS study with its potential cystic fibrosis therapy, the C1 corrector, GLPG2222, that bodes well for the biotech's plans to start Phase II studies of triple combinations of its investigational cystic fibrosis therapies, in collaboration with its US partner AbbVie Inc.
The positive results also move the Belgian company forward in its race to catch up with the US company
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Merck & Co. won European Commission approval for Winrevair on top of other medicines for pulmonary arterial hypertension and expects an initial EU launch in Germany.
The company, in its new profitable era, is bringing in new leadership, with Amgen VP of medical affairs for rare diseases Greg Friberg and recently retired Roche Partnering head James Sabry.
Bluebird, Vertex and Sarepta are starting to see some commercial gene therapy traction and expect momentum to pick up in the second half, while hemophilia remains a challenging area.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
